BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10600008)

  • 41. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
    Moldenhauer G; Henne C; Karhausen J; Möller P
    Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species.
    Temme S; Zacharias M; Neumann J; Wohlfromm S; König A; Temme N; Springer S; Trowsdale J; Koch N
    J Biol Chem; 2014 Jan; 289(2):639-53. PubMed ID: 24214983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments.
    Warmerdam PA; Long EO; Roche PA
    J Cell Biol; 1996 Apr; 133(2):281-91. PubMed ID: 8609162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
    Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
    J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human germinal center B cells differ from naive and memory B cells by their aggregated MHC class II-rich compartments lacking HLA-DO.
    Chalouni C; Banchereau J; Vogt AB; Pascual V; Davoust J
    Int Immunol; 2003 Apr; 15(4):457-66. PubMed ID: 12663675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM.
    Robbins NF; Hammond C; Denzin LK; Pan M; Cresswell P
    Hum Immunol; 1996 Jan; 45(1):13-23. PubMed ID: 8655355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased endosomal delivery of major histocompatibility complex class II-invariant chain complexes in dynamin-deficient cells.
    Wang K; Peterson PA; Karlsson L
    J Biol Chem; 1997 Jul; 272(27):17055-60. PubMed ID: 9202021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and HLA-DR but not HLA-DM in trophoblast cells.
    Ranella A; Vassiliadis S; Mastora C; Valentina M; Dionyssopoulou E; Athanassakis I
    Hum Immunol; 2005 Jan; 66(1):43-55. PubMed ID: 15620461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
    Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
    J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape.
    Zwart W; Griekspoor A; Kuijl C; Marsman M; van Rheenen J; Janssen H; Calafat J; van Ham M; Janssen L; van Lith M; Jalink K; Neefjes J
    Immunity; 2005 Feb; 22(2):221-33. PubMed ID: 15723810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
    Ullrich HJ; Döring K; Grüneberg U; Jähnig F; Trowsdale J; van Ham SM
    Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13163-8. PubMed ID: 9371817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR.
    Roche PA; Teletski CL; Karp DR; Pinet V; Bakke O; Long EO
    EMBO J; 1992 Aug; 11(8):2841-7. PubMed ID: 1639058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
    Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
    J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HLA-DM is expressed on the cell surface and colocalizes with HLA-DR and invariant chain in human Langerhans cells.
    Andersson T; Patwardhan A; Emilson A; Carlsson K; Scheynius A
    Arch Dermatol Res; 1998 Dec; 290(12):674-80. PubMed ID: 9879837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
    van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.